215 related articles for article (PubMed ID: 37400616)
1. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.
Su F; Yang X; Yin J; Shen Y; Tan L
Ann Surg Oncol; 2023 Nov; 30(12):7461-7471. PubMed ID: 37400616
[TBL] [Abstract][Full Text] [Related]
2. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F; Pala L; Sala I; Oriecuia C; De Pas T; Specchia C; Graffeo R; Pagan E; Queirolo P; Pennacchioli E; Colleoni M; Viale G; Bagnardi V; Gelber RD
BMJ; 2021 Dec; 375():e066381. PubMed ID: 34933868
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
6. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
7. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Association of pathological response with long-term survival outcomes after neoadjuvant immunotherapy: A meta-analysis.
Wei C; Sun H; Hu J; Ma Z; Cao B
Int Immunopharmacol; 2024 May; 133():112078. PubMed ID: 38685176
[TBL] [Abstract][Full Text] [Related]
10. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
11. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
12. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study.
Al-Kaabi A; van der Post RS; van der Werf LR; Wijnhoven BPL; Rosman C; Hulshof MCCM; van Laarhoven HWM; Verhoeven RHA; Siersema PD
Acta Oncol; 2021 Apr; 60(4):497-504. PubMed ID: 33491513
[TBL] [Abstract][Full Text] [Related]
13. Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Ostoros G; Hettle R; Georgoulia N; Berktas M; Chander P; Diaz Perez I; Couto AM; Eichinger C; Field P; Morten P
Expert Rev Anticancer Ther; 2023; 23(12):1305-1313. PubMed ID: 37850939
[TBL] [Abstract][Full Text] [Related]
14. Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.
Zhu J; Tao J; Dai Z; Tan Y; Jiang L; Wang Q; Lang J
Front Oncol; 2021; 11():771546. PubMed ID: 35111667
[TBL] [Abstract][Full Text] [Related]
15. Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis.
Sakamoto K; Okabayashi K; Matsui S; Seishima R; Shigeta K; Kitagawa Y
J Gastrointest Surg; 2022 Oct; 26(10):2227-2236. PubMed ID: 35829868
[TBL] [Abstract][Full Text] [Related]
16. Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
Buyse M; Saad ED; Burzykowski T; Regan MM; Sweeney CS
Oncologist; 2022 Apr; 27(4):266-271. PubMed ID: 35380717
[TBL] [Abstract][Full Text] [Related]
17. Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.
Wainberg ZA; Xie J; Valderrama A; Yin L; Zhang S; Shih CS; Bhagia P; Gu Q; Shitara K; Janjigian YY; Tabernero J
Clin Cancer Res; 2023 Apr; 29(7):1360-1367. PubMed ID: 36652563
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortes J; Ramsey S; Briggs A; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
J Natl Compr Canc Netw; 2020 Aug; 18(8):1096-1104. PubMed ID: 32755985
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]